Core Viewpoint - TC BioPharm (Holdings) PLC announced a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval [1] Group 1: Dividend Announcement - The company plans to hold a general meeting of shareholders on December 30, 2024, to declare the dividend, which will be payable to shareholders owning stock at the close of trading on January 2, 2025 [2] - The CEO expressed satisfaction with the announcement, highlighting shareholder support during challenging market conditions [3] Group 2: Company Focus and Clinical Trials - TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T-cell therapies for cancer, with human efficacy data in acute myeloid leukemia [3] - The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using proprietary CryoTC technology [4] Group 3: Stock Performance - As of the last check, TCBP stock was down 1.94% to $0.46 during the premarket session [5]
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend